Literature DB >> 8406821

Tumor necrosis factor alpha, interleukin-1 alpha, interleukin-6, and prostaglandin E2 production in murine peritoneal macrophages infected with Ehrlichia risticii.

A M van Heeckeren1, Y Rikihisa, J Park, R Fertel.   

Abstract

Ehrlichia risticii is a gram-negative obligate intracellular bacterium which primarily infects macrophages and crypt epithelial cells in the intestinal wall and is the etiologic agent of Potomac horse fever. To understand the pathogenesis of the disease, we tested whether E. risticii induces inflammation-associated products in thioglycolate-induced mouse peritoneal macrophages. Mouse peritoneal macrophages produced larger amounts of interleukin-1 alpha (IL-1 alpha) but lower levels of tumor necrosis factor alpha (TNF-alpha), IL-6, and prostaglandin E2 (PGE2) when exposed to live or killed E. risticii than when exposed to Escherichia coli lipopolysaccharide (LPS). Preincubation of macrophages with live or killed E. risticii suppressed TNF-alpha, IL-6, and PGE2 generation but not IL-1 alpha production in response to LPS. Murine gamma interferon treatment of macrophages did not influence TNF-alpha, IL-1 alpha, IL-6, or PGE2 production regardless of exposure to E. risticii. Intracellular cyclic AMP was significantly greater in E. risticii-infected macrophages than in uninfected macrophages. These results suggest that increased levels of IL-1 alpha but not TNF-alpha or PGE2 production by macrophages may be primarily involved in the pathogenesis of the disease caused by E. risticii. Increased intracellular concentration of cyclic AMP in infected macrophages may be chiefly responsible for the high level of IL-1 alpha and inhibition of TNF-alpha production in response to LPS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406821      PMCID: PMC281162          DOI: 10.1128/iai.61.10.4333-4337.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Colonic and small intestinal response to intravenous prostaglandin F2 alpha and E2 in man.

Authors:  G J Milton-Thompson; J H Cummings; A Newman; J A Billings; J J Misiewicz
Journal:  Gut       Date:  1975-01       Impact factor: 23.059

2.  Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides.

Authors:  A L Steiner; C W Parker; D M Kipnis
Journal:  J Biol Chem       Date:  1972-02-25       Impact factor: 5.157

3.  Formation of antibodies to prostaglandins in the yolk of chicken eggs.

Authors:  R Fertel; J Z Yetiv; M A Coleman; R D Schwarz; J E Greenwald; J R Bianchine
Journal:  Biochem Biophys Res Commun       Date:  1981-10-15       Impact factor: 3.575

4.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor.

Authors:  D A Flick; G E Gifford
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

5.  A macrophage-monocyte cell line from a dog with malignant histiocytosis.

Authors:  M L Wellman; S Krakowka; R M Jacobs; G J Kociba
Journal:  In Vitro Cell Dev Biol       Date:  1988-03

6.  Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP.

Authors:  Y Katakami; Y Nakao; T Koizumi; N Katakami; R Ogawa; T Fujita
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

7.  Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.

Authors:  S L Kunkel; M Spengler; M A May; R Spengler; J Larrick; D Remick
Journal:  J Biol Chem       Date:  1988-04-15       Impact factor: 5.157

8.  Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins.

Authors:  M E Snider; R H Fertel; B S Zwilling
Journal:  Cell Immunol       Date:  1982-12       Impact factor: 4.868

9.  Reduced immune responsiveness and lymphoid depletion in mice infected with Ehrlichia risticii.

Authors:  Y Rikihisa; G C Johnson; C J Burger
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

10.  Ultrastructural study of ehrlichial organisms in the large colons of ponies infected with Potomac horse fever.

Authors:  Y Rikihisa; B D Perry; D O Cordes
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

View more
  6 in total

1.  Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages.

Authors:  V Jubier-Maurin; R A Boigegrain; A Cloeckaert; A Gross; M T Alvarez-Martinez; A Terraza; J Liautard; S Köhler; B Rouot; J Dornand; J P Liautard
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Bone Mineralization of Broiler Chicks Challenged with Salmonella enteritidis Fed Diet Containing Probiotic (Bacillus subtilis).

Authors:  A A Sadeghi
Journal:  Probiotics Antimicrob Proteins       Date:  2014-12       Impact factor: 4.609

3.  Absence of tumor necrosis factor alpha, interleukin-6 (IL-6), and granulocyte-macrophage colony-stimulating factor expression but presence of IL-1beta, IL-8, and IL-10 expression in human monocytes exposed to viable or killed Ehrlichia chaffeensis.

Authors:  E H Lee; Y Rikihisa
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Protein kinase A-mediated inhibition of gamma interferon-induced tyrosine phosphorylation of Janus kinases and latent cytoplasmic transcription factors in human monocytes by Ehrlichia chaffeensis.

Authors:  E H Lee; Y Rikihisa
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expression in human monocytes through sustained reduction of IkappaB-alpha and activation of NF-kappaB.

Authors:  E H Lee; Y Rikihisa
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Live Brucella spp. fail to induce tumor necrosis factor alpha excretion upon infection of U937-derived phagocytes.

Authors:  E Caron; T Peyrard; S Köhler; S Cabane; J P Liautard; J Dornand
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.